ClinicalTrials.gg
TerminatedNCT04232631Updated Nov 13, 2026

Non-Invasive Testing to Evaluate Wound Healing in Diabetes

An observational study in Diabetic Foot Ulcer, sponsored by University of Texas Southwestern Medical Center. Terminated at 1 site in United States. Open to participants aged 18 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by University of Texas Southwestern Medical Center · Observational

How we know

Why this study was terminated
Study was stopped as the company that owns the hyperspectral imaging devices required their return.
Updated Nov 13, 2026Now TerminatedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
157
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetic Foot by University of Texas Southwestern Medical Center — none open to participants now, none under way, none of them phase 3. Diabetic Foot · University of Texas Southwestern Medical Center.

Started
2021
with 1 other
Observational
7 of 15
none open now
Registered
12th of 15
by date

Among the 15 studies in Diabetic Foot by University of Texas Southwestern Medical Center, this one is one of 2 that started in 2021, is one of 7 observational ones, and was the 12th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

None of the 15 studies in Diabetic Foot by University of Texas Southwestern Medical Center is open now. The open studies under Diabetic Foot, anywhere →

Where they have run

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Diabetic Foot by University of Texas Southwestern Medical Center as a file.
02

Study summary

Normal group: We will collect normative data from healthy individuals to include baseline data, screening, and images. Up to 500 people will be enrolled and can include normal healthy volunteers, staff and students/trainees. Data will be collected one time with no follow up.

Patient group: We will prospectively collect data using one instrument (camera) (SnapshotNIR, Kent Imaging, Calgary, Alberta, Canada). We will collect non-contact imaging data before surgeries, during surgeries (if feasible), and during follow-up clinic visits. We will collect vascular data, demographic medical history, wound characteristics and measurements, frequency of debridement, off-loading, and clinic visits from existing medical records. We will collect lab data such as cultures glycosylated hemoglobin, hemoglobin and hematocrit, ESR, CRP and eGFR obtained per standard of care.

Imaging with this device is research-only.

Read the detailed description

This is a prospective, observational study. All medical and surgical care provided to the patient group will be standard of care.

Patient group: Once a patient is identified as requiring vascular intervention or lower extremity ulceration (includes lower extremity wound of any cause, a surgical incision, a flap or graft) and consent to participation, their lower extremity will be imaged. They will be imaged preop, intraop (if feasible) and on post-op day 1 + or - 7 days if they require surgery and for each surgery related to the ulceration. They will also be imaged once a month in follow up for up to a total of 6 months or healing of the wound, determined by study physician.

Normal group: The normal group will have one-time imaging and data collection.

The Kent instrument does not touch the patient and is being evaluated to measure perfusion to predict wound healing, flap survival and amputation level healing. They are research only and not standard of care, and are not being used to determine care in the patient group.

03

Conditions studied

  • Diabetic Foot Ulcer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Investgator's patients, normal healthy volunteers

Eligibility criteria

Investigator patients

Inclusion Criteria:

  • Patient of the investigators
  • Diagnosis of diabetes mellitus
  • One or more moderate to severe diabetic foot ulcers/infections
  • 18-89 years of age

Exclusion Criteria:

  • Non-diabetic
  • Is pregnant or plans to become pregnant
  • Is nursing or actively lactating
  • Developmental disability/significant psychological disorder that in the opinion of the investigator could impair the subject's ability to provide , participate in the study protocol or record study measures, including untreated schizophrenia, bipolar disorder and psychiatric hospitalization within the last 2 years.
  • Active alcohol or substance abuse in the opinion of the investigator that could impair the subject's ability to provide informed consent, participate in the study protocol or record study materials
  • Patients with a history of poor compliance

Normal Healthy volunteers

Inclusion Criteria:

  • Over 18
  • Have a foot

Exclusion Criteria:

  • Foot wounds
  • Non-English speaking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
157 participants (actual)
Patient registry
No

Groups and cohorts

  • patients with diabetic foot ulcers

    * Patient of the investigators * Diagnosis of diabetes mellitus * One or more moderate to severe diabetic foot ulcers/infections * 18-89 years of age

    Device: SnapshotNIR, Kent Imaging

  • Normal healthy volunteers

    over 18 years of age have a foot

    Device: SnapshotNIR, Kent Imaging

Interventions

  • DeviceSnapshotNIR, Kent Imaging

    Vascular imaging device

06

What researchers measure

Primary outcomes

  1. Evaluating the effectiveness of SnapshotNIR device to measure perfusion to predict wound healing, flap survival and amputation level healing. The device will report the oxygen saturation, oxyhemoglobin and deoxyhemoglobin levels in superficial tissue.

    To evaluate the effectiveness of the Kent instrument to measure perfusion to predict wound healing, flap survival and amputation level healing.

    Time frame: Three years

07

Study locations

1 site
  • UT Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared. This was an investigator-initiated observational study, and data sharing was not contemplated in the study protocol or the participant consent process.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2021 to primary completion in Nov 2026, 66 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Sep 2026 → Nov 2026 and completion Sep 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2019
First posted
Jan 18, 2020
StartActual
Apr 28, 2021
Primary completionActual
Nov 2, 2026was Sep 2026
CompletionActual
Nov 2, 2026was Sep 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Terminated Study was stopped as the company that owns the hyperspectral imaging devices required their return.
changed Nov 13, 2026
Primary completion
Sep 2026→Nov 2, 2026 (actual)
Nov 13, 2026
Study completion
Sep 2026→Nov 2, 2026 (actual)
Nov 13, 2026
Enrollment
700 (estimated)→157 (actual)
Nov 13, 2026
Documents
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Suspended→Terminated
    Why stopped Study was stopped as the company that owns the hyperspectral imaging devices required their return.
    Documents Study protocol ↗ posted
    Primary completion Sep 2026→Nov 2, 2026 (now actual)
    Study completion Sep 2026→Nov 2, 2026 (now actual)
    Enrollment 700 (estimated)→157 (actual)
    + 4 other changes: verification date, responsible party, contact details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04232631
Responsible party
Peter Crisologo, DPM (Associate Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Jan 18, 2020
Start date
Apr 28, 2021
Primary completion
Nov 2, 2026
Completion
Nov 2, 2026
Last update
Nov 13, 2026

Study contacts

Peter A Crisologo, DPM
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion